Integrating Precision Medicine with Nanotechnology to Overcome Drug Resistance in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 1095
Special Issue Editor
Interests: drug resistance; ABC transporters; natural products; nanomaterials; tyrosine kinase inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Integrating precision medicine with nanotechnology offers a transformative approach to overcoming drug resistance in cancer, a major challenge in oncology. Precision medicine tailors treatments to a patient's unique genetic, molecular, and environmental profile, enabling targeted therapies that address specific cancer characteristics. However, drug resistance often undermines these efforts, as cancer cells adapt to evade therapies. Nanotechnology enhances precision medicine by delivering drugs with unprecedented accuracy, using nanoparticles to target cancer cells while sparing healthy tissue. Novel nanoscale carriers can also enable gene-editing-based therapy, bypass resistance mechanisms, and enhance therapeutic efficacy. Additionally, nanoparticles can co-deliver multiple drugs or combine therapeutics with imaging agents, facilitating real-time monitoring and personalized treatment adjustments. This Special Issue brings together cutting-edge research and perspectives on how this synergistic approach can transform cancer treatment by merging nanotechnology's precision delivery with genomic insights from precision medicine.
Dr. Yan Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- precision medicine
- nanotechnology
- drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
